1) Strategic Rebranding and Leadership Vision
- Starling Oncology has rebranded from its previous name to better reflect its focus as a national leader in value-based oncology care.
- The rebranding coincides with a pivotal moment in the company's evolution, emphasizing coordinated care and technology-driven innovation.
- CEO Dan Virnich highlighted the importance of the name change in aligning with the company's growth and operational achievements.

2) Strong Financial Performance and Growth Metrics
- Q2 2026 revenue reached approximately $161 million, a 35% YoY increase, driven by growth in the specialty pharmacy segment.
- Positive adjusted EBITDA of $0.2 million marked the second profitable quarter since going public, an improvement from a loss of $4.1 million YoY.
- Specialty pharmacy revenue grew 57.6% YoY to $98.6 million, while patient services revenue increased 5.3% YoY to $58.8 million.
- Gross profit improved to $27.2 million, with an overall gross margin of 16.8%, up from 14.6% YoY.

3) Operational Developments and New Initiatives
- The company is set to launch the Starling Nexus provider portal in mid-August, aimed at enhancing provider engagement and operational efficiencies.
- New capitated contracts are expected to add approximately 80,000 lives and $50 million in annualized revenue, with expansions into Nevada and Oregon.
- Achieved exclusivity in California, adding 230,000 capitated lives and an estimated $6 million in annualized revenue.
- Medical loss ratio (MLR) for Q2 was 85.5%, with expectations to remain between 80% to 90% over the next year.

4) Challenges and Adjusted Guidance
- The anticipated statewide payer relationship in Florida has been delayed from Q3 to Q4, impacting short-term revenue expectations.
- Despite this, the company raised its full-year revenue guidance to $650 million to $670 million, including $150 million from capitated revenue.
- Adjusted EBITDA guidance was narrowed to a range of $2 million to $7 million, reflecting ongoing investments in business growth.

5) Future Outlook and Investor Considerations
- Starling Oncology is optimistic about continued growth in capitated contracts and operational efficiencies, projecting a 100% increase in capitated revenue for 2027.
- The company is focused on maintaining profitability and scaling operations, with a strong emphasis on enhancing its service offerings and network capabilities.
- There is a commitment to transparency and improved communication with investors regarding operational metrics and financial health.

Bottom line: Starling Oncology is positioned for sustained growth and profitability, bolstered by strategic rebranding, strong financial performance, and expanding operational capabilities. The company’s focus on value-based care and new contract acquisitions supports a positive outlook for shareholders.